Research programme: renal and lung cancer gene therapy - AdvantageneAlternative Names: ADV 005; Adv-005; TKI therapy
Latest Information Update: 16 Jul 2016
At a glance
- Originator Advantagene
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Lung cancer; Renal cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Renal-cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-cancer in USA
- 01 Sep 2006 Preclinical trials in Renal cancer in USA (unspecified route)